Maximum insulin dose in patients admitted to the intensive care units with severe COVID ‐19 in the “Cross ICU Searchable Information System” study: A multicenter retrospective cohort study
Journal of Diabetes Investigation · 2025
DOI: 10.1111/jdi.14380 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Emi Ushigome und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Insulin, COVID-19, Intensive Care Units, Hypoglycemic Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Themen: Intensivpflege
Abstract (Originalsprache)
Aims
This study aimed to determine the maximum daily insulin dose (MDI) and associated factors in critically ill patients with coronavirus disease 2019 (COVID‐19) receiving insulin therapy, under ventilator and/or extracorporeal membrane oxygenation (ECMO) management. Materials and Methods This cross‐sectional analysis used the Cross ICU Searchable Information System data from a Japanese multicenter retrospective observational cohort study of critically ill patients with COVID‐19 receiving ventilation and/or ECMO, from February 2020 to March 2022. Maximum daily insulin dose was determined, and factors associated with it and maximum daily insulin dose per body weight were assessed using linear regression analysis.
Results
The analysis included 788 patients. Their mean age, glycated hemoglobin level, maximum daily insulin dose, and time from admission to the maximum daily insulin dose were 65.2 ± 13.0 years, 7.0 ± 1.5% (53.0 ± 7.1 mmol/mol), 46.0 ± 43.6 U/day, and 7.3 ± 7.0 days, respectively. Male sex (β = 6.902, P = 0.034), body mass index (β = 1.020, P = 0.001), glycated hemoglobin (β = 12.272, P < 0.001), and having renal failure (β = 20.637, P = 0.003) were independent determinants of maximum daily insulin dose. Age (β = 0.004, P = 0.035), glycated hemoglobin (β = 0.154, P < 0.001), and having renal failure (β = 0.282, P = 0.004) were independent determinants of maximum daily insulin dose per body weight.
Conclusions
In patients with COVID‐19 on ventilator and/or ECMO management, the maximum daily insulin dose reached after about 1 week of hospitalization was approximately 46.0 U/day. Glycated hemoglobin and renal failure were both associated with the maximum daily insulin dose and maximum daily insulin dose per body weight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- ICU Collaboration Network, Bunkyo-ku, Tokyo, Japan.
ORCID-Profile: Emi Ushigome, Masahide Hamaguchi
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Ushigome, E., Imai, D., Hamaguchi, M., Hashimoto, S., & Fukui, M. (2025). Maximum insulin dose in patients admitted to the intensive care units with severe COVID ‐19 in the “Cross ICU Searchable Information System” study: A multicenter retrospective cohort study. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14380
Vancouver
Ushigome E, Imai D, Hamaguchi M, Hashimoto S, Fukui M. Maximum insulin dose in patients admitted to the intensive care units with severe COVID ‐19 in the “Cross ICU Searchable Information System” study: A multicenter retrospective cohort study. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.14380
BibTeX
@article{Ushigome2025,
author = {Ushigome, Emi and Imai, Dan and Hamaguchi, Masahide and Hashimoto, Satoru and Fukui, Michiaki},
title = {Maximum insulin dose in patients admitted to the intensive care units with severe COVID ‐19 in the “Cross ICU Searchable Information System” study: A multicenter retrospective cohort study},
journal = {Journal of Diabetes Investigation},
year = {2025},
doi = {10.1111/jdi.14380}
}
EUVIMED